A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer

Nuclear Medicine Communications

Volumn 33, Issue 10, 2012, Pages 1039-1047

  Bal, Chandrasekhar ^a   Chandra, Prem ^a   Kumar, Ajay ^a,b   Dwivedi, Sadanand ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

differentiated thyroid cancer; equivalence trial; noninferiority trial; optimum dose; remnant ablation

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROXINE;

ABLATION THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG UPTAKE; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NECK; OPTIMAL DRUG DOSE; RANDOMIZED CONTROLLED TRIAL; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

ABLATION TECHNIQUES; ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA; CELL DIFFERENTIATION; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; LOGISTIC MODELS; MALE; MIDDLE AGED; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865708018     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835674af     Document Type: Article

References (31)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154:787-803. (Pubitemid 43997716)
3. British Thyroid Association, Royal College of Physicians. Guidelines for the management of thyroid cancer. 2nd ed. London: Royal College of Physicians; Available at: http://www.british-thyroid-association.org; 2007.
4. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2007; 96:1447-1463.
5. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306. (Pubitemid 28065257)
6. Sherman SI. Thyroid carcinoma. Lancet 2003; 361:501-511. (Pubitemid 36173719)
7. Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77: 2574-2580.
8. Bal CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab 2004; 89:1666-1673. (Pubitemid 38507919)
9. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 96:1447-1463. (Pubitemid 32374886)
10. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2000; 52:765-773. (Pubitemid 30409270)
11. Doi SA,Woodhouse NJ, Thalib L, Onitilo A. Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited. Clin Med Res 2007; 5:87-90.
12. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 2007; 92:28-38. (Pubitemid 46075005)
13. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995; 311:485.
14. Jones B, Jarvis P, Lewis JA. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313:36-39. (Pubitemid 26229889)
15. Blackwelder WC. Equivalence trials. In: Redmond CK, Colton T, editors. Biostatistics in clinical trials. New York: Wiley; 2001. pp. 179-185.
16. Blackwelder WC.'Proving the null hypothesis' in clinical trials. Control Clin Trials 1982; 3:345-353. (Pubitemid 13113168)
17. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1976; 34:585-611.
18. White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978; 37:849-857. (Pubitemid 8344907)
19. Samuel AM, Rajashekharrao B. Radioiodine therapy for well differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 1994; 35:1944-1950. (Pubitemid 24376609)
20. Agarwal S, Rao RS, Parikh DM, Parikh HK, Borges AM, Sampat MB. Histologic trends in thyroid cancer 1969-1993: a clinico-pathological analysis of the relative proportion of anaplastic carcinoma of the thyroid. J Surg Oncol 1996; 63:251-255. (Pubitemid 27009242)
21. Thomas SR, Maxon HR, Kereiakes JG, Saenger EL. Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer. Radiology 1977; 122:731-737. (Pubitemid 8037648)
22. Snyder J, Gorman C, Scanion P. Thyroid remnant ablation: questionable pursuit of an ill-defined goal. J Nucl Med 1983; 24:659-665. (Pubitemid 13016085)
23. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastasis and micrometastasis from differentiated thyroid cancer. Thyroid 1997; 7:183-187. (Pubitemid 27190577)
24. American Joint Committee on Cancer-Thyroid. AJCC Cancer Staging Handbook. 6th ed. New York: Springer; 2002. pp. 89-98.
25. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89:1638-1644. (Pubitemid 37464133)
26. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports parallel group randomized trials. Lancet 2001; 357:1191-1194. (Pubitemid 32378696)
27. Torgerson D, Campbell M. Unequal randomization can improve the economic efficiency of clinical trials. J Health Serv Res Policy 1997; 2:81-85. (Pubitemid 27196934)
28. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366:1663-1673.
29. Mallick U, Harmer C, Yap B,Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366:1674-1685.
30. Bal CS, Chandra P, Kumar A, Dwivedi SN. A randomized noninferiority trial to determine the optimum dose of radioiodine for remnant ablation in differentiated thyroid cancer [abstract]. Endocr Rev 2010;
31. (Suppl 1):S1674.